Healthy
Conditions
Brief summary
The purpose of this trial is to compare the pharmacokinetics (PK), safety, tolerability and immunogenicity of a single dose of 300 mg tralokinumab administered as a 1 × X mL subcutaneous (SC) injection with Device A and 2 × Y mL consecutive SC injections with Device B.
Detailed description
This is a single center, randomized, open label, 2 period, 2 sequence cross over trial designed to compare the PK and to evaluate the safety, tolerability and immunogenicity of 300 mg tralokinumab administered as a 1 × X mL SC injection with Device A (test treatment \[T\]) and 2 × Y mL consecutive SC injections with Device B (reference treatment \[R\]) in healthy subjects. Additionally, the experience of tralokinumab being administered with Device A compared to Device B will be evaluated. After being informed about the study and the potential risks, all subjects giving written informed consent will be enrolled and randomized to 1 of 2 treatment sequences, Sequence TR or Sequence RT in a 1:1 ratio (i.e., subjects receive the 2 treatments in the specified order).
Interventions
DRUGTralokinumab administered as 1 × X mL with Device A
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
DEVICETralokinumab administered as 2 × Y mL with Device B
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Sponsors
LEO Pharma
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female aged 18 to 55 years (both included) at the time of Screening. * Female subjects of childbearing potential must use a highly effective form of birth control throughout the trial and at least for 16 weeks after last administration of the investigational medicinal product (IMP) and must have a negative serum pregnancy test at Screening.
Exclusion criteria
* Systemic (non biologic) or topical treatment within 21 days prior to first dose administration unless in the opinion of the Investigator the medication will not interfere with the trial procedures or compromise safety. * Active tuberculosis or history of incompletely treated tuberculosis based on medical history or medical report. * History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at Screening, or the subject taking antiretroviral medications as determined by medical history and/or subject's verbal report. * History of a clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to randomization. * History of a helminth parasitic infection within 6 months prior to the date of informed consent that has not been treated with or has failed to respond to standard of care therapy. * History of anaphylaxis or severe allergic reaction following any biologic therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the serum concentration time curve from time 0 (pre dose) extrapolated to infinity (AUC0-inf) in each Treatment Period derived from all observed concentrations in the time period pre dose to 16 weeks post dose | In each Treatment Period pre-dose to 16 weeks post dose |
| Area under the serum concentration time curve from time 0 (pre dose) to time of last quantifiable concentration in each Treatment Period derived from all observed concentrations in the time period pre dose to 16 weeks post dose. | In each Treatment Period pre-dose to 16 weeks post dose |
| Observed maximum serum concentration (Cmax) in each Treatment Period derived from all observed concentrations in the time period pre dose to 16 weeks post dose | In each Treatment Period pre-dose to 16 weeks post dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time corresponding to observed maximum serum concentration (tmax) | In each Treatment Period pre-dose to 16 weeks post dose | — |
| Terminal half life (t½) in each Treatment Period derived from all observed concentrations in the time period pre dose to 16 weeks post dose | In each Treatment Period pre-dose to 16 weeks post dose | — |
| Apparent total body clearance (CL/F), calculated as dose/AUC0-inf | In each Treatment Period pre-dose to 16 weeks post dose | (AUC0-inf: Area under the serum concentration time curve from time 0 (pre dose) extrapolated to infinity) |
| Apparent volume of distribution based on terminal phase (Vz/F), calculated as t½/ln(2)*CL/F | In each Treatment Period pre-dose to 16 weeks post dose | (t½: Terminal half life; CL/F: Apparent total body clearance) |
| Number of treatment emergent adverse events (TEAEs) from Day 1 to Day 126 and of TEAEs from Day 127 to Day 239 (number of adverse events [AEs] emerging with each treatment) | Day 1 to Day 239 | — |
| Presence of binding and neutralizing anti-drug antibodies (ADAs) at Days 1 (pre dose), 15, and 57 of Treatment Periods 1 and 2 and Day 239 | Day 1 to Day 239 | — |
Countries
Germany
Contacts
STUDY_DIRECTORMedical Expert
LEO Pharma
Outcome results
None listed